See more : AVIC Electromechanical Systems Co.,Ltd (002013.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Changzhou Qianhong Biopharma CO.,LTD, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Treasury Metals Inc. (TML.TO) Income Statement Analysis – Financial Results
- Purple Group Limited (PPE.JO) Income Statement Analysis – Financial Results
- Everest Re Group, Ltd. (0U96.L) Income Statement Analysis – Financial Results
- Deezer S.A. (DEEZR.PA) Income Statement Analysis – Financial Results
- PT Indosterling Technomedia TBK (TECH.JK) Income Statement Analysis – Financial Results
Changzhou Qianhong Biopharma CO.,LTD (002550.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.qhsh.com.cn
About Changzhou Qianhong Biopharma CO.,LTD
Changzhou Qianhong Biopharma CO.,LTD engages in the research and development, production, and sale of bio-pharmaceutical products with a focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; kallidinogenase kallikrein for use in the treatment of microcirculation disorders; and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. In addition, the company exports its products. Changzhou Qianhong Biopharma CO.,LTD was founded in 1971 and is headquartered in Changzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.81B | 2.30B | 1.87B | 1.67B | 1.68B | 1.32B | 1.07B | 776.39M | 757.05M | 814.61M | 860.78M | 728.59M | 737.65M | 1.14B | 743.80M | 471.64M | 285.60M |
| Cost of Revenue | 1.05B | 1.41B | 1.04B | 873.60M | 873.29M | 675.48M | 513.89M | 274.04M | 248.37M | 336.43M | 494.31M | 410.40M | 439.96M | 836.58M | 482.94M | 281.86M | 176.61M |
| Gross Profit | 768.81M | 888.97M | 833.63M | 794.00M | 801.86M | 646.20M | 551.58M | 502.35M | 508.68M | 478.18M | 366.48M | 318.19M | 297.69M | 308.19M | 260.85M | 189.78M | 108.98M |
| Gross Profit Ratio | 42.38% | 38.59% | 44.46% | 47.61% | 47.87% | 48.89% | 51.77% | 64.70% | 67.19% | 58.70% | 42.57% | 43.67% | 40.36% | 26.92% | 35.07% | 40.24% | 38.16% |
| Research & Development | 97.08M | 88.31M | 71.18M | 69.14M | 65.38M | 67.29M | 63.51M | 44.39M | 41.27M | 53.32M | 41.68M | 33.12M | 24.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 46.28M | 40.04M | 43.70M | 43.88M | 39.64M | 38.16M | 32.99M | 30.56M | 22.87M | 23.12M | 21.89M | 20.09M | 17.79M | 76.61M | 58.52M | 40.99M | 31.15M |
| Selling & Marketing | 302.30M | 421.76M | 463.44M | 367.89M | 359.74M | 320.50M | 248.49M | 215.77M | 198.19M | 175.81M | 112.83M | 89.67M | 81.79M | 48.10M | 41.19M | 27.49M | 17.72M |
| SG&A | 348.58M | 461.80M | 507.13M | 411.76M | 399.37M | 358.67M | 281.47M | 246.33M | 221.06M | 198.93M | 134.72M | 109.76M | 99.59M | 124.70M | 99.71M | 68.48M | 48.87M |
| Other Expenses | 118.79M | 90.44M | 92.93M | 86.34M | 92.89M | 1.81M | 671.58K | 4.31M | 4.43M | 17.21M | 6.68M | 9.25M | 11.58M | 8.96M | 924.98K | 95.26K | 179.17K |
| Operating Expenses | 564.45M | 640.55M | 671.24M | 567.25M | 557.64M | 507.08M | 424.85M | 344.17M | 310.43M | 292.31M | 218.84M | 183.28M | 152.98M | 129.95M | 103.10M | 71.06M | 50.94M |
| Cost & Expenses | 1.61B | 2.06B | 1.71B | 1.44B | 1.43B | 1.18B | 938.74M | 618.20M | 558.80M | 628.73M | 713.15M | 593.69M | 592.94M | 966.53M | 586.04M | 352.92M | 227.55M |
| Interest Income | 11.30M | 5.64M | 1.60M | 6.02M | 3.00M | 122.17M | 112.00M | 116.56M | 104.89M | 84.65M | 71.86M | 49.32M | 28.65M | 428.07K | 264.51K | 514.73K | 184.04K |
| Interest Expense | 6.17M | 5.23M | 1.66M | 8.44M | 18.72M | 19.05M | 16.42M | 16.01M | 9.04M | 970.36K | 623.05K | 1.96M | 4.20M | 11.25M | 4.59M | 5.83M | 1.74M |
| Depreciation & Amortization | 72.97M | 68.31M | 64.32M | 73.64M | 67.83M | 63.38M | 63.09M | 27.32M | 20.49M | 21.31M | 21.58M | 17.21M | 12.88M | 11.05M | 10.93M | 10.26M | 9.92M |
| EBITDA | 282.87M | 442.64M | 281.45M | -75.34M | 366.50M | 336.65M | 293.54M | 308.62M | 323.54M | 309.16M | 238.49M | 205.64M | 195.47M | 186.18M | 166.29M | 123.34M | 58.39M |
| EBITDA Ratio | 15.59% | 16.85% | 12.14% | 17.74% | 25.14% | 25.88% | 27.62% | 40.09% | 44.02% | 38.03% | 28.09% | 28.82% | 26.50% | 17.18% | 22.52% | 26.79% | 21.23% |
| Operating Income | 204.36M | 360.01M | 158.15M | 225.63M | 300.24M | 252.03M | 213.04M | 260.95M | 298.58M | 268.88M | 209.50M | 177.31M | 167.04M | 165.43M | 150.89M | 107.16M | 46.59M |
| Operating Income Ratio | 11.26% | 15.63% | 8.44% | 13.53% | 17.92% | 19.07% | 20.00% | 33.61% | 39.44% | 33.01% | 24.34% | 24.34% | 22.64% | 14.45% | 20.29% | 22.72% | 16.31% |
| Total Other Income/Expenses | -833.05K | 323.96K | 39.39K | -4.36M | 266.50K | 1.81M | 671.58K | 4.02M | 4.41M | 17.20M | 6.66M | 55.83M | 11.57M | -4.04M | -6.55M | -8.73M | -8.64M |
| Income Before Tax | 203.52M | 360.33M | 209.38M | -169.12M | 300.51M | 253.84M | 213.72M | 264.54M | 302.99M | 286.08M | 216.16M | 186.50M | 178.61M | 174.37M | 150.78M | 107.25M | 46.72M |
| Income Before Tax Ratio | 11.22% | 15.64% | 11.17% | -10.14% | 17.94% | 19.21% | 20.06% | 34.07% | 40.02% | 35.12% | 25.11% | 25.60% | 24.21% | 15.23% | 20.27% | 22.74% | 16.36% |
| Income Tax Expense | 24.85M | 40.42M | 23.04M | -21.49M | 43.59M | 42.79M | 38.81M | 39.86M | 40.70M | 43.92M | 34.47M | 27.78M | 26.76M | 23.85M | 25.08M | 16.87M | 1.14M |
| Net Income | 181.86M | 323.41M | 181.08M | -147.63M | 262.56M | 221.35M | 183.00M | 224.46M | 267.15M | 245.04M | 187.02M | 161.80M | 152.25M | 150.53M | 125.69M | 90.44M | 45.63M |
| Net Income Ratio | 10.02% | 14.04% | 9.66% | -8.85% | 15.67% | 16.75% | 17.18% | 28.91% | 35.29% | 30.08% | 21.73% | 22.21% | 20.64% | 13.15% | 16.90% | 19.18% | 15.98% |
| EPS | 0.14 | 0.25 | 0.14 | -0.12 | 0.21 | 0.17 | 0.14 | 0.18 | 0.21 | 0.19 | 0.14 | 0.13 | 0.12 | 0.16 | 0.13 | 0.09 | 0.05 |
| EPS Diluted | 0.14 | 0.25 | 0.14 | -0.12 | 0.21 | 0.17 | 0.14 | 0.18 | 0.21 | 0.19 | 0.14 | 0.13 | 0.12 | 0.16 | 0.13 | 0.09 | 0.05 |
| Weighted Avg Shares Out | 1.30B | 1.28B | 1.25B | 1.25B | 1.25B | 1.27B | 1.27B | 1.25B | 1.27B | 1.29B | 1.29B | 1.28B | 1.23B | 963.38M | 957.66M | 964.68M | 960.53M |
| Weighted Avg Shares Out (Dil) | 1.30B | 1.28B | 1.25B | 1.25B | 1.25B | 1.30B | 1.31B | 1.25B | 1.27B | 1.29B | 1.29B | 1.28B | 1.23B | 963.38M | 957.66M | 964.68M | 960.53M |
Source: https://incomestatements.info
Category: Stock Reports